摘要
目的观察前列益康胶囊对非特异性前列腺炎患者血清及前列腺液中前列腺素E_2(PGE_2)及白细胞介素-8(IL-8)水平的影响。方法 80例非特异性前列腺炎患者随机分为对照组及试验组,各40例。对照组给予普乐安片2.0 g,每天3次,口服;试验组给予前列益康胶囊1.5 g,每天3次,口服。2组均持续治疗4周。比较2组患者治疗前后血清及前列腺液中PGE_2、IL-8水平及治疗有效率。结果试验组治疗有效率为92.50%(37/40例),对照组为75.00%(30/40例,P<0.05)。治疗后,试验组与对照组血清PGE_2分别为(159.76±16.34),(190.65±17.56)ng·L^(-1),血清IL-8分别为(2.28±0.32),(3.08±0.22)ng·L^(-1),差异有统计学意义(P<0.05)。治疗后,试验组与对照组前列腺液PGE_2分别为(227.46±20.84),(309.46±19.39)ng·L^(-1),前列腺液IL-8分别为(3.12±0.43),(4.77±0.67)ng·L^(-1),差异有统计学意义(P<0.05)。2组均未出现明显的药物不良反应。结论前列益康胶囊能够显著降低非特异性前列腺炎患者血清及前列腺液中PGE_2及IL-8水平,具有较好的临床疗效。
Objective To evaluate the clinical effect of Qianlie Yikang capsules on the levels of prostaglandin E_2( PGE_2) and interleukin-8( IL-8) in serum and prostatic fluid in patients with nonspecific prostatitis. Methods Eighty patients with nonspecific prostatitis were randomly divided into control group and treatment group,40 cases in each group. Control group was orally given Pule'an tablets 2. 0 g,3 times a day. Treatment group was treated with Qianlie Yikang capsules 1. 5 g,3 times a day,orally. Before and after treatment,the levels of serum and prostatic fluid PGE_2,IL-8 and clinical efficiency in two groups were compared. Results The clinical efficiency of treatment group was92. 50%( 37/40 cases),had significant difference with that in control group,which was 75. 00%( 30/40 cases,P〈0. 05). After treatment,the serum PGE_2 of treatment group and control group were( 159. 76 ± 16. 34),( 190. 65 ± 17. 56) ng·L^(-1),IL-8 were( 2. 28 ± 0. 32),( 3. 08 ±0. 22)ng· L^(-1),with significant difference( P〈0. 05). After treatment,the prostatic fluid PGE_2 of treatment group and control group were( 227. 46 ±20. 84),( 309. 46 ± 19. 39) ng·L^(-1), IL-8 were( 3. 12 ±0. 43),( 4. 77 ± 0. 67) ng · L^(-1),with significant difference( P〈0. 05). There was no significant adverse reactions in two groups.Conclusion The Qianlie Yikang capsules can significantly reduce theserum and prostatic fluid PGE_2,IL-8 levels in patients with nonspecific prostatitis,and have good clinical effect.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2017年第13期1198-1200,共3页
The Chinese Journal of Clinical Pharmacology
基金
吉林省科技发展计划基金资助项目(20130206038YY)